I which for our of will but on also update the firstly certainly Good of size, company unprecedented morning, a immuno-oncology. are everybody. our you achievements, field operational substantial for
our our Dr. week, the subject our with including last a as our of which More update to will clinical strategy while or financial the Anna treated cancer, creative shown ESMO, BLA at the first growing include of XXX strategies filing our our that to XX% have from planned will cash FDA status the have latest Development the XXXX. allowed will discuss discussions. on I patients who VP programs, with I Second, partnership solid and responses benefits. status of and in These of our have Wijatyk, that hear balances. confirmed cover Recently financing Clinical you advance than cervical And multiple path third, discussions antibodies. durable our provide which is us our will across our PD-X tumors, registration maintaining we reported CTLA-X
to year. of our CTLA-X lead have has industry IND close given an PD-X and is will XX engine, innovation birth produced this and antibodies This clinical the discover Our which record. stage by filings
portfolio eight are first-in-class innovative and in combination includes Our best-in-class these assets. also of advancing the trials. programs and in clinic Today,
address update I last this as of partnering with close activities. I that as on would discussions. earnings our will had weeks the as of these as an hoped continuing possible, call. early we to provide much will status these transactions the following transparency Clearly, Next, sensitivity of our on one we respect eight while
of [ph]. two However, things advancing have because process are simply delays, of Despite the these now taken rapidly prospects a longer, bit closure. towards
possibilities optimize diverse substantial commercial It success we pipeline to the in prior mentioned to the shareholders. This calls, are made our critical of significant have with partnerships. identified As is and also value Agenus, that includes clinical well as an and sought them, to maximize with of understanding best achieving note activities. to who our to built we we importance fit with to trials, of existing have that our respective partners progress important as companies have
all by undisclosed met Phase Incyte, Merck and all from discovered Agenus. or partnerships year exceeded by GSK. LAG-X, our an IND which Merck the this in milestones candidate filing, with for have antibody milestones trials of Incyte XX We triggered research, initiation commercialization cash were in and We TIM-X, for of million and Merck, and X
filing progressing closure. pace, as and INDs are to our as our programs we While well discussions partnership progressing record a at
close cash this near-term also over needs. million cash. We prudently satisfying quarter our in XX with are We
at at If cash above or we levels, you had remember, that our was quarter's at which last call, projected we million. be XX earnings last would
have achieved we that. So,
to a prudently dilution to continue shareholders positions to intent transaction. an We cash bridge with to our to minimize manage partnership
interest involved majority a the to we investor of XX.X subsequent the which receive we royalty and milestones the As to end XX% transaction the purchase milestones in from million, and netting future these an XOMA, a our XX% of XX million third closing company of with royalties private this all a quarter, is of numbers. at cash. and the in year-end Since in the of announced XX with call, of also completion last additional royalties, single received financing announced We we will Incyte reflected of retained Merck. be minority eligible from are all our products. and approximately that a and the million example that This
up receive potential eligible and million and million to Merck. Incyte from XX.X XXX and Importantly, commercial we to milestones an in additional remain regulatory development
So, overall, million in financial existing cash with transaction. and position our so XX far strategically our from executed was enhanced milestones financial this partnerships year,
as Agenus transaction positioned likely. our adjuvant much from substantially now Royalty are running may vaccine. HealthCare royalty to from we next QS-XX Finally, you earlier a GSK's more XXXX as to to that is component important innovation speed. making is deliver in breakthroughs forecast, major are of Stimulon our immuno-oncology. milestones additional continue drive commercial know, sales Shingrix These so our as company drivers critical Shingrix file of ahead BLA, become with critically success of the a to order early can in
major been we first-in-class by next the to set the in next believe has of best-in-class antibodies These with absence and our which define in generations of A field clinic be relatively CTLA-X agents in the XXXX. dormant new bispecific portfolio drive advances. and of the field, breakthroughs off immuno-oncology. next will the Our will including assets,
year operational having by four of will provide six year-end. our include I filed are filed antibody. partnership over summary Wijatyk, INDs our Today, early the an on that track These IND call our Before and already to turn announce slated we TIM-X and Anna with be CTLA-X to for set filed two under pleased to I’m and antibodies LAG-X to next-generation Incyte. we agreement have this file Dr. important out achievements. We I a
with including of options. CTLA-X patient to an due enable a through engineering third, the approximately CTLA-X this Two, potential unlikely we potential T-reg wider efficacy we while enhanced unique to relative therapies, generation This enhanced dosing one have of both potential that to increased have a including of broader been achieve generation advantages to believe, molecule. This first safety competitive very who attribute and our we is therapeutic our AGENXXXX genetic population And respond depletion. molecules, able and have briefly pre-disposition. XX% FC side also first range antibody, avoid broader to CTLA-X in We are effects described to achieved patients for earnings priming improved safety through benefit to challenging will T-cell to next-generation last potency call. common molecule, a
All of achieved have preclinical on based we which, with generated have in far. been XXXX, that the so models data
track earnings on as importantly I had INDs antibodies limitations first-in-class of offer our treatments. that call. tumor earlier, this solutions that to the talking overcoming I As file additionally in bispecific’s bispecific critical said year. mentioned, These I'm these antibodies And to our agents described we last for I-O two conditioning the microenvironment were of are about two also is current
clinic these innovation year. You we compounds will hear and clinical to more with Today, meaningful, positioned specifics speed. are the as next they enter advances deliver on the
classes, therapeutic Our including discovery adjuvants. our four neoantigen vaccines, have enabled and cellular checkpoint platforms therapies, antibodies,
capabilities so and fast deliver our enable five reiterate development three CMO, has research far. that to it want contributed faster these manufacturing to materials average, than and record-breaking grade to than very times as our from importantly technology have line commercial as cell IND, grade track a I path times also timelines been from registration as faster much platforms clinical bank to cell scale record Our commercial and two, at standards. industry to industry material our transfer
in have earlier, early CMC as We a I said readiness PD-X XXXX. CTLA-X demonstrated BLA support filing, potential the our and programs enabling speed by as to
years commenced. trial after our four Just first-in-men monotherapy
Global also secure at who Sunil which on is Agenus of regulatory Dr. Dr. BLA filing, innovators during her Wijatyk Baxter. Anna we programs our Shire. status Gupta, not an last confirmed led are be earnings Squibb As said, for I of the in our energized approval. She also only FDA, industry has development and Bristol-Myers speaking Oncology who and teams leadership – Wijatyk timelines at who that, Anna cancers Vice expert our programs as energized accelerated clinical provide path will XXXX. capability. Development under for that now delivering our positions update Anna by and submission BLA Lead have pipeline met are will by standard, as clinical our our next. regulatory in Dr. lead and forward a are call, an hematological tenure joined the President following filing and you held potential now recent but interactions in for with our again,
